Kevin Li

Dr. Kevin Li is a Partner at DT Capital responsible for healthcare and life science investments. Prior to DT, Kevin was the Chief Scientific Officer of China Nuokang Biopharma (Nasdaq:NKBP), a leading biopharmaceutical company in China, and a Partner at HBM BioMed China, a Shanghai‐based venture capital fund affiliated with the HBM Bioventures, and focused on biomedical investment opportunities. Kevin has over 10 years of professional experience in biomedical sciences, healthcare investment and entrepreneurship. PhD Indiana University; Postdoc Stanford University.